Robinhood shares gain on Q2 beat, as user and crypto growth accelerate
BP4 S.r.l., a ten percent owner of MILESTONE SCIENTIFIC INC. (NASDAQ:MLSS), has reported selling shares of the company’s common stock. According to a Form 4 filing with the Securities and Exchange Commission, the sales occurred in two transactions on June 16 and June 18, 2025. The company, currently valued at $68.3 million, has seen its stock decline nearly 5% over the past six months. According to InvestingPro analysis, the stock appears overvalued at current levels.
The transactions involved the sale of 10,056 shares at a price of $0.8951 on June 16, and 1,693 shares at $0.88 on June 18. The total value of shares sold was $10490, with prices ranging from $0.88 to $0.8951. Following these transactions, BP4 S.r.l. directly owns 9,445,490 shares of Milestone Scientific (NYSE:MLSS). InvestingPro subscribers have access to 6 additional key insights about MLSS, including detailed analysis of its financial health score of 2.28 (rated as ’Fair’) and comprehensive valuation metrics.
The sales were executed by Dr. Pedro Palau, Liquidator, as indicated in the signature.
In other recent news, Milestone Scientific Inc. reported ending the first quarter with a strong financial position, having $2.2 million in cash and no debt, according to Benchmark analysts. The company is making strides in the Medicare market for pain management with its CompuFlo System, which has already secured coverage from three out of twelve Medicare Administrative Contractors (MACs). This development is seen as a potential growth driver in a market segment that accounts for approximately 3.6 million procedures annually. Milestone Scientific is also targeting reimbursement from private payors, which could expand the market to nine million procedures. Benchmark has reiterated a Speculative Buy rating with a $1.25 price target, based on a projection of five times the anticipated 2030 revenue of $26 million. Additionally, Milestone Scientific has appointed Shanth Thiyagalingam to its Board of Directors to support its expansion strategies. Thiyagalingam brings over two decades of experience in the medical device and pharmaceutical sectors, enhancing the company’s strategic execution capabilities. The company continues to focus on its innovative injection technologies, aiming to improve precision and efficiency in medical and dental procedures.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.